Pharmac’s $1.2M Stent Deal Signals Major Shift in Medical Device Procurement Strategy

Drug-eluting stents are a cornerstone of modern cardiology, widely used in procedures to treat coronary artery disease—the leading cause of death globally.

New Zealand’s public health system is poised for a significant cost-saving breakthrough, as Pharmac advances a provisional national supply agreement for coronary drug-eluting stents, projected to save $1.2 million annually while maintaining clinical quality and access.

Associate Health Minister David Seymour announced that the proposal—now open for consultation—marks a turning point in how high-value medical devices are procured, following over a decade of stalled reform.

If approved, the agreement would grant Principal Supply Status to Medtronic New Zealand beginning 1 June 2026, covering approximately 65% of all drug-eluting stents used in public hospitals over a three-year term. The remaining 35% of supply would remain open to alternative brands, ensuring clinical flexibility and patient-specific treatment choices.

A High-Impact Device in Cardiac Care

Drug-eluting stents are a cornerstone of modern cardiology, widely used in procedures to treat coronary artery disease—the leading cause of death globally. These tiny mesh tubes are inserted into narrowed or blocked arteries and gradually release medication to prevent re-narrowing, significantly improving patient outcomes and reducing repeat interventions.

In New Zealand, thousands of such procedures are performed annually, making stent procurement a high-cost, high-volume category within hospital budgets. Even modest efficiencies in purchasing can translate into substantial system-wide savings.

From Paralysis to Reform: Unlocking Procurement Efficiency

Seymour emphasized that the agreement reflects the first tangible gains from a major overhaul of medical device procurement, which had remained largely unchanged for 13 years.

“Medical device procurement was effectively paralysed for over a decade. By modernising the system last year—making it more efficient, transparent, and accountable—we are now seeing real financial and clinical benefits,” he said.

The updated procurement model introduces a shared responsibility framework between Pharmac and Health New Zealand (HNZ), leveraging the strengths of both agencies. While each body retains responsibility for specific categories of devices, they collaborate closely on high-impact procurements such as this.

Clinician-Led Design to Safeguard Quality

A key feature of the proposal is its clinician-driven design, developed in consultation with the Interventional Cardiology Advisory Group. This group, comprising frontline specialists, played a central role in:

• Defining clinical requirements for stents

• Evaluating the suitability of Medtronic’s products

• Shaping procurement criteria to reflect real-world usage

This approach aims to address a longstanding concern in public procurement: balancing cost efficiency with clinical autonomy and patient outcomes.

“The clinicians who use these devices every day understand what works best. Their input ensures that cost savings do not come at the expense of quality care,” Seymour noted.

Market Competition Preserved

Despite granting Medtronic a dominant share, the proposal deliberately avoids a single-supplier model. By reserving 35% of procurement for alternative suppliers, the system maintains competitive pressure and allows hospitals to select devices tailored to specific patient needs.

Health economists note that such “principal supply with competitive margin” models are increasingly used internationally to achieve cost reductions while avoiding supply risks and vendor lock-in.

Transition Plan and Industry Engagement

If the proposal proceeds, Pharmac and Health NZ will jointly oversee a nationwide transition plan, including:

• Coordinated rollout across public hospitals

• Training and education programs delivered by Medtronic

• Ongoing support to ensure clinical teams adapt smoothly

The agencies are also seeking broad stakeholder input before finalising the agreement. Feedback is invited from health professionals, procurement specialists, hospital managers, and suppliers, reflecting a commitment to inclusive policy design.

Wider Implications for the Health System

The projected $1.2 million annual savings, while modest in the context of total health expenditure, signal a broader shift toward strategic procurement as a lever for system sustainability.

With healthcare costs rising globally—driven by ageing populations, advanced technologies, and workforce pressures—governments are increasingly focusing on value-based purchasing to stretch limited resources.

Seymour underscored this philosophy: “When you spend better, you can afford more. Every dollar saved here is a dollar that can be reinvested into frontline care.”

Consultation Open

Stakeholders have until 4:00 PM, Tuesday 28 April to provide feedback on the proposal. Submissions can be sent to: devices@pharmac.govt.nz

The final decision will depend on consultation outcomes, but officials suggest the proposal could become a template for future national procurement strategies across other medical device categories.

If implemented successfully, it may mark the beginning of a more data-driven, clinician-informed, and fiscally disciplined era in New Zealand’s public healthcare system.